New research from the American Thoracic Society (ATS) 2023 International Conference outlines how artificial intelligence may be able to improve diagnosis and prognosis of interstitial lung disease (ILD), as reported by Dr Imre Noth of the University of Virginia.
Dr Noth comments that differentiating between ILDs with similar clinical characteristics, such as idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis, can prove challenging. Likewise, predicting rapid progression in IPF is another area of difficulty for clinicians managing patients with ILD.
He details findings from studies using proteomic and other biomarkers to help make diagnoses, predict progression of disease, and determine response to therapy. In some studies, artificial intelligence provided superior predictive accuracy than did clinical modeling.
In another development relating to ILD, Dr Noth reports on a phase 3 study of sotatercept, a first-in-class fusion protein which demonstrated efficacy in pulmonary arterial hypertension (PAH), a common comorbidity in ILD. The median increase in 6-minute walk distance among the sotatercept group was 34.4 m compared with 1 m in the placebo group, a significant difference with implications for patients with ILD and comorbid PAH.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Interstitial Lung Disease Highlights From ATS 2023 - Medscape - Jun 14, 2023.
Comments